Bio Green Med: 15min KDJ Death Cross, Bearish Marubozu on Chart

Based on the 15-minute chart for Bio Green Med, there has been a recent development that warrants attention. The KDJ Death Cross and Bearish Marubozu at 14:00 on September 15th indicates a shift in the momentum of the stock price towards a downward trend. This suggests that the sellers are currently in control of the market and there is a high likelihood that the bearish momentum will continue.

Modular Medical Inc. (NASDAQ: MODD), a leader in innovative insulin pump technology, has been making significant strides in the medical device sector. The company has recently announced several key milestones that underscore its commitment to transforming diabetes care.

In a recent development, Modular Medical completed a clinical study of its MODD1 insulin pump, which received FDA clearance. The study involved nine clinicians with Type 1 diabetes, providing real-world experience and feedback for the company's next-generation Pivot pump. This pump is designed to cater to the $3 billion adult "almost-pumpers" market, focusing on user-friendliness and affordability Modular Med Inc Stock Price, News & Analysis^[1].

The company has also announced the successful completion of its MODD1 cartridge production, with over 6,000 units manufactured. This production line is now transitioning to produce cartridges for the upcoming Pivot product, which is expected to be submitted for FDA clearance in October 2025. The Pivot pump is set to be the first tubeless, removable 3 milliliter patch pump in the market, targeting adult "almost-pumpers" with its user-friendly and affordable design .

Modular Medical's collaboration with Level Ex to develop gamified training modules for the Pivot pump is another notable advancement. Level Ex, known for creating the diabetes management game 'Level One', will integrate pump training into their platform. These training modules aim to address pump adoption barriers through gamified learning, making diabetes management more accessible and user-friendly .

The company has also achieved a significant milestone with the first human use of its MODD1 insulin pump in a real-world setting. Under FDA institutional review board approval, the MODD1 pump is currently delivering insulin to a clinician with Type 1 diabetes. The company plans to expand testing to multiple clinicians across multiple sites in mid-August 2025 .

Additionally, Modular Medical has appointed Jeff Goldberg to its Board of Directors. Goldberg brings extensive experience in healthcare, life sciences, and medical device leadership, particularly in generic insulin development. His appointment aligns with Modular Medical's focus on developing user-friendly and affordable insulin delivery technology .

These developments highlight Modular Medical's commitment to advancing diabetes care through innovative and accessible insulin delivery solutions. As the company continues to make strides in the medical device sector, investors and healthcare professionals should keep a close eye on its progress.